Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases

Verhaak, Eline; Schimmel, Wietske C. M.; Gehring, Karin; Emons, Wilco H. M.; Hanssens, Patrick E. J.; Sitskoorn, Margriet M.

Published in:
Journal of Cancer Research and Clinical Oncology

DOI:
10.1007/s00432-020-03400-w

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Tilburg University Research Portal

Citation for published version (APA):
Verhaak, E., Schimmel, W. C. M., Gehring, K., Emons, W. H. M., Hanssens, P. E. J., & Sitskoorn, M. M. (2021). Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases. Journal of Cancer Research and Clinical Oncology, 147(4), 1157-1167. https://doi.org/10.1007/s00432-020-03400-w

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 13. Oct. 2023
Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases

Eline Verhaak1,2,3 · Wietske C. M. Schimmel1,2,3 · Karin Gehring1,2,3 · Wilco H. M. Emons4 · Patrick E. J. Hanssens1,2 · Margriet M. Sitskoorn1,2

Received: 14 August 2020 / Accepted: 18 September 2020 © The Author(s) 2020

Abstract
Purpose Increasingly more patients with multiple (> 4) brain metastases (BM) are being treated with stereotactic radiosurgery (SRS). Preserving patients’ health-related quality of life (HRQoL) is an important treatment goal. The aim of this study was to assess (individual) changes in HRQoL in patients with 1–10 BM over time.
Methods A total of 92 patients were assessed before (n = 92) and at 3 (n = 66), 6 (n = 53), and 9 (n = 41) months after Gamma Knife radiosurgery (GKRS), using the Functional Assessment of Cancer Therapy-Brain (FACT-Br). The course of HRQoL was analyzed using linear mixed models. Clinical minimally important differences were used to evaluate individual changes.
Results At group level, patients’ physical well-being worsened, whereas emotional well-being improved over 9 months. Scores on other HRQoL subscales did not change significantly. Number (1–3 versus 4–10) and volume (small, medium, and large) of BM did not influence HRQoL over time, except for the subscale additional concerns; medium intracranial tumor volume was associated with less additional concerns. On the individual level as well, physical well-being declined while emotional well-being improved in most patients over 9 months after GKRS. At patient level, however, most patients had both declines as well as improvements in the different HRQoL aspects.
Conclusion Our results indicate that even in patients with up to 10 BM, both at group and individual subscale level, aspects of HRQoL remained stable over nine months after GKRS, except for an improvement in emotional well-being and a decline in physical well-being. Nevertheless, HRQoL scores varied considerably at the individual patient level.
Trail registration number ClinicalTrials.gov Identifier: NCT02953756, November 3, 2016.

Keywords Brain metastases · Health-related quality of life · Stereotactic radiosurgery · Gamma Knife radiosurgery

Introduction
Approximately 10–35% of patients with advanced cancer develop brain metastases (BM) during the course of their disease (Achrol et al. 2019; Arvold et al. 2016). BM are an important cause of morbidity and mortality (Ahluwalia et al. 2014; Tabouret et al. 2012) and the prevalence is rising, mainly due to increased surveillance and improvements in systemic therapies that allow longer survival, which in turn allows for BM to develop (Nayak et al. 2012; Tsao 2015). Preserving health-related quality of life (HRQoL) is a highly important treatment goal in this patient group (Tsao 2015; van der Meer et al. 2018; Wong et al. 2008). HRQoL is a multidimensional construct that includes, amongst others, health, social, emotional, and functional well-being (Chen et al. 2012). Overall, previous studies demonstrated stable HRQoL in patients with BM after
stereotactic radiosurgery (SRS) (Bragstad et al. 2017; Habets et al. 2016; Kirkpatrick et al. 2015; Skeie et al. 2017). However, for the physical aspects of HRQoL, contradictory results have been found (Verhaak et al. 2020). Three studies reported a decline in the physical aspect of HRQoL (Habets et al. 2016; Kotecha et al. 2017; Miller et al. 2017), whereas three other studies reported stable scores over time (Bragstad et al. 2017; Kirkpatrick et al. 2015; Skeie et al. 2017).

SRS is an increasingly used treatment for patients with multiple (> 4) BM. Cumulative intracranial metastatic volume has become a more important criterion than the number of BM when selecting patients eligible for SRS (Hunter et al. 2012; Nabors et al. 2014; Soliman et al. 2016). Thus far, HRQoL has mostly been evaluated in patients with 1–4 BM (in two studies, less than 10% of the patients had 4–6 BM). Number of BM (up to 4) was not predictive of HRQoL over time in previous studies (Bragstad et al. 2017; Habets et al. 2016; Skeie et al. 2017). HRQoL was associated with (change in) Karnofsky Performance Status (KPS): higher KPS was predictive of higher or stable HRQoL (Bragstad et al. 2017; Habets et al. 2016; Skeie et al. 2017; van der Meer et al. 2018), and in two studies, larger baseline volume of BM was associated with worse HRQoL over time (Bragstad et al. 2017; Habets et al. 2016), while in two other studies no such association was found (Skeie et al. 2017; van der Meer et al. 2018).

Group-level changes in HRQoL may mask potential variation over time in HRQoL among individual patients (Verhaak et al. 2020). Van der Meer et al. (2018) showed that HRQoL remained stable at group level 6 months after SRS, but scores varied substantially at the individual level (both at scale and patient level). Despite this study, detailed evaluation of individual HRQoL changes at subscale level remains relatively scarce (Verhaak et al. 2020).

The aim of this study is to examine several aspects of HRQoL at 3, 6, and 9 months after Gamma Knife radiosurgery (GKRS) in patients with up to 10 BM, both at group and individual level. In addition, baseline predictors of change in HRQoL were examined.

Materials and methods

Data of patients from the prospective longitudinal observational CAR-Study A (ClinicalTrials.gov Identifier: NCT02953756) were analyzed. This study was approved by the Medical Ethics Committee (file NL53472.028.15). Baseline evaluations of cognitive functioning (Schimmel et al. 2019), HRQoL (Verhaak et al. 2019a), and over time evaluations of fatigue (Verhaak et al. 2019b) in our patient group have been previously published.

Patients and procedures

Adult patients with 1–10 newly diagnosed BM on a contrast-enhanced volumetric MRI scan were recruited. Eligibility criteria were previously published in detail (Verhaak et al. 2019a). Most relevant inclusion criteria were total volume of the BM ≤ 30 cm³, KPS ≥ 70, and expected survival > 3 months. Exclusion criteria included small cell lung cancer, meningeal disease, or prior BM treatment.

Assessments (approximately 60 min), including six neuropsychological tests (Wefel et al. 2011) and three self-report questionnaires concerning HRQoL (FACT.org 2017), fatigue (Smets et al. 1995), and anxiety and depression (Zigmond and Snaith 1983), were performed on the day of and before Gamma Knife radiosurgery (GKRS) and at 3, 6, and 9 months after GKRS. Follow-up assessments were scheduled on the same day and before follow-up MRI scans and consults. All patients gave written informed consent.

Treatment

Standard SRS procedures were performed with a Leksell Gamma Knife (Elekta AB). All patients received a dose of 18–25 Gy with 99–100% coverage of the target. Dose limits for organs at risk were 18 Gy for the brainstem and 8 Gy for the optic chiasm or optic nerves.

Measures

Clinical and socio-demographic characteristics were extracted from patients’ medical records.

HRQoL was assessed with the Functional Assessment of Cancer Therapy-Brain (FACT-Br), a self-report questionnaire specific for patients with brain tumors (FACT.org 2017; Thavarajah et al. 2014; Weitzner et al. 1995). The FACT-Br is commonly used to measure both general HRQoL and specific concerns associated with brain tumors using five subscales. The four (core) subscales of the FACT-Br focus on physical, social, emotional, and functional well-being. The disease-specific subscale ‘additional concerns’ of the FACT-Br was specifically developed for patients with brain tumors. In addition, the following scale scores were calculated: (1) the FACT-General total score, which is based on the first four subscales, measures overall HRQoL and can be used in various groups of patients with cancer; (2) the FACT-Brain total score, which is the FACT-General total score plus the fifth brain tumor-specific subscale (additional concerns); (3) the trial outcome index, which includes the
subscales psychical well-being, functional well-being, and additional concerns, is a summary index of physical/functional outcomes (FACIT.org 2017). For all scales, higher scores indicate better HRQoL (Cella et al. 1993; FACIT.org 2017; Thavarajah et al. 2014; Weitzner et al. 1995). Published data from a normative sample, consisting of 1075 persons from the general US adult population (age range = 18–91, 51% female), provided by Brucker et al. (2005), were used to compare HRQoL scores of the patients with BM to.

The total volumetric sum of contrast-enhancing BM was determined at baseline, 3, 6, and 9 months, using T1-weighted MRI scans with 1.5 mm slice thickness. Complete response was defined as a disappearance of all BM (no longer visible). Partial response was defined as a ≥ 65% decrease in total tumor volume and no new BM. Intracranial progression was defined as a ≥ 73% increase in total tumor volume or new BM. Stable disease was defined as no complete response, no partial response, or no intracranial progression (Lin et al. 2015).

Statistical analyses
Statistical analyses were performed with SPSS version 25 and R (R Core Team), version 3.6.1. To control the false discovery rate due to multiple testing a corrected alpha was used per hypothesis, based on the procedure of Benjamini–Hochberg (Benjamini and Hochberg 1995)."
Table 1  Patient characteristics

|                                | No. of patients included at baseline (%) | No. of patients with ≥ 1 follow-up HRQoL assessment (%) | No. of patients without follow-up HRQoL assessment (baseline only) (%) |
|--------------------------------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------|
| Number of participants        | 92 (100%)                                | 66 (72%)                                              | 26 (28%)                                                          |
| Age in years, median (range)   | 63.0 (31–80)                             | 63.0 (31–80)                                          | 61.5 (39–76)                                                      |
| Sex, male                      | 47 (51.1%)                               | 31 (47.0%)                                            | 16 (61.5%)                                                       |
| Educational level\(^a\)        |                                          |                                                        |                                                                  |
| Low                            | 28 (30.4%)                               | 16 (24.2%)                                            | 12 (46.2%)                                                       |
| Middle                         | 37 (40.2%)                               | 29 (43.9%)                                            | 8 (30.8%)                                                        |
| High                           | 27 (29.3%)                               | 21 (31.8%)                                            | 6 (23.1%)                                                        |
| KPS, median (range)            | 90 (70–100)                              | 90 (70–100)                                           | 90 (70–100)                                                      |
| 70–80                          | 33 (35.9%)                               | 21 (31.8%)                                            | 12 (46.2%)                                                       |
| 90–100                         | 59 (64.1%)                               | 45 (68.2%)                                            | 14 (53.8%)                                                       |
| RPA                            |                                          |                                                        |                                                                  |
| Class 1                        | 16 (17.4%)                               | 13 (19.7%)                                            | 3 (11.5%)                                                        |
| Class 2                        | 76 (82.6%)                               | 53 (80.3%)                                            | 23 (88.5%)                                                       |
| GPA                            |                                          |                                                        |                                                                  |
| Class 2                        | 15 (16.3%)                               | 12 (18.2%)                                            | 3 (11.5%)                                                        |
| Class 3                        | 60 (65.2%)                               | 42 (63.6%)                                            | 18 (69.2%)                                                       |
| Class 4                        | 27 (29.3%)                               | 12 (18.2%)                                            | 5 (19.2%)                                                        |
| Number of BM                   |                                          |                                                        |                                                                  |
| 1–3                            | 55 (59.8%)                               | 41 (62.1%)                                            | 14 (53.8%)                                                       |
| 4–10                           | 37 (40.2%)                               | 25 (37.9%)                                            | 12 (46.2%)                                                       |
| Total volume of BM cm\(^3\), median (range)\(^b\) | 5.6 (0.02–31.1)                         | 5.4 (0.02–31.1)                                       | 5.8 (0.04–31.0)                                                 |
| Small (< 4.8 cm\(^3\))        | 40 (43.5%)                               | 29 (43.9%)                                            | 11 (42.3%)                                                       |
| Middle (4.8–12.6 cm\(^3\))    | 25 (27.2%)                               | 17 (25.8%)                                            | 8 (30.8%)                                                        |
| Large (> 12.6 cm\(^3\))       | 27 (29.3%)                               | 20 (30.3%)                                            | 7 (26.9%)                                                        |
| Primary site                   |                                          |                                                        |                                                                  |
| Lung (NSCLC)                   | 55 (59.8%)                               | 40 (60.6%)                                            | 15 (57.7%)                                                       |
| Renal                          | 15 (16.3%)                               | 12 (18.2%)                                            | 3 (11.5%)                                                        |
| Melanoma                       | 12 (13.0%)                               | 6 (9.1%)                                              | 6 (23.1%)                                                        |
| Breast                         | 6 (6.5%)                                 | 5 (7.6%)                                              | 1 (3.8%)                                                         |
| Other                          | 4 (4.3%)                                 | 3 (4.5%)                                              | 1 (3.8%)                                                         |
| Systemic therapy\(^c\)         |                                          |                                                        |                                                                  |
| No                             | 39 (42.4%)                               | 27 (40.9%)                                            | 12 (46.2%)                                                       |
| Yes                            | 53 (57.6%)                               | 39 (59.1%)                                            | 14 (53.8%)                                                       |
| Overall survival in months, median (range) | 11.8 (8.6 to 15.0) | 17.1 (10.5 to 23.7) | 2.7 (1.7 to 3.7) |
| HRQoL                          |                                          |                                                        |                                                                  |
| Physical well-being, mean (SD) | 22.7 (4.8)                               | 22.8 (4.9)                                            | 22.3 (4.6)                                                       |
| Social well-being, mean (SD)   | 23.0 (5.5)                               | 22.9 (5.1)                                            | 23.2 (5.9)                                                       |
| Emotional well-being, mean (SD)| 16.0 (4.7)                               | 16.1 (4.4)                                            | 15.8 (5.5)                                                       |
| Functional well-being, mean (SD)| 17.9 (6.1)                              | 18.5 (5.3)                                            | 16.3 (7.6)                                                       |
| FACT-General, mean (SD)        | 79.6 (15.6)                              | 80.4 (13.9)                                           | 77.7 (19.5)                                                      |
| Additional concerns, mean (SD) | 50.5 (11.2)                              | 51.1 (11.5)                                           | 49.0 (10.5)                                                      |
| FACT-Brain, mean (SD)          | 130.1 (24.0)                             | 131.5 (22.2)                                          | 126.7 (28.3)                                                    |
| Trial outcome index, mean (SD) | 91.1 (18.8)                              | 92.5 (18.1)                                           | 87.6 (20.4)                                                      |

BM brain metastases, FACT-Brain Functional Assessment of Cancer Therapy-Brain, FACT-General Functional Assessment of Cancer Therapy-General, GPA graded prognostic assessment, HRQoL health-related quality of life, KPS Karnofsky Performance Status, No. number, NSCLC non-small cell lung cancer, RPA recursive partitioning analysis, SD standard deviation

\(^a\)Educational level according to Verhage (Verhage 1964) (7 levels): low = 1–4, middle = 5, high = 6–7

\(^b\)Total volume of brain metastases by patient (two patients had a total volume of BM > 30 cm\(^3\), 31.1 and 31.0 cm\(^3\), on the MRI-scan used for treatment planning)

\(^c\)Before or at time of Gamma Knife radiosurgery
Table 2 Health-related quality of life of patients with BM

| HRQoL subscales | General population (n = 1075)<sup>a</sup> Mean (SD) | Patients with BM Mean raw HRQoL scores (SD) | Patients with BM versus general population<sup>a</sup> 9 months after GKRS |
|-----------------|-----------------------------------------------|---------------------------------------------|---------------------------------------------|
|                 | Baseline (n = 92) 3 months (n = 66) 6 months (n = 53) 9 months (n = 41) | z value p* Effect size z value p* Effect size | Baseline (n = 92) 3 months (n = 66) 6 months (n = 53) 9 months (n = 41) z value p* Effect size |
| Physical well-being | 22.7 (5.4) 20.7 (5.6) 21.0 (5.1) 21.2 (5.1) | 0.00 1.000 .00 − 1.78 .075 .28 |
| Social well-being | 19.1 (6.8) 23.0 (5.3) 23.1 (4.0) 22.6 (5.0) | 5.50 <.001 .57 3.77 <.001 .59 |
| Emotional well-being | 19.9 (4.8) 16.0 (4.7) 17.5 (3.8) 18.2 (4.5) | −7.79 <.001 .81 − 2.53 .011 .40 |
| Functional well-being | 18.5 (6.8) 17.9 (6.1) 17.3 (5.5) 17.6 (5.8) | −0.85 .397 .09 0.19 .851 .03 |
| FACT-General | 80.1 (18.1) 79.6 (15.6) 78.5 (14.2) 79.3 (14.3) | −0.26 .791 .03 0.32 .750 .05 |
| Additional concerns<sup>b</sup> | 50.5 (11.2) 52.2 (11.3) 52.8 (10.6) 53.7 (10.4) | |
| FACT-Brain<sup>b</sup> | 130.1 (24.0) 130.7 (22.9) 132.1 (22.6) 134.7 (21.7) | |
| Trial outcome index<sup>b</sup> | 91.1 (18.8) 90.1 (19.2) 91.3 (18.2) 93.6 (17.3) | |

<sup>a</sup>BM brain metastases, FACT-Brain Functional Assessment of Cancer Therapy-Brain, FACT-General Functional Assessment of Cancer Therapy-General, GKRS Gamma Knife radiosurgery, HRQoL health-related quality of life, n number of patients, SD standard deviation

<sup>b</sup>Normative data of general population (n = 1075) of Brucker et al. (2005), Normative data not available/applicable. *Corrected alpha of 0.02 using the Benjamini–Hochberg procedure (Benjamini and Hochberg 1995). Bold text indicates statistical significance. Higher scores indicate better HRQoL (Cella et al. 1993; FACIT.org 2017; Thavarajah et al. 2014; Weitzner et al. 1995)
common histology was non-small cell lung cancer (NSCLC; 60%). Median total volume of BM was 5.64 cm$^3$ (Table 1).

Follow-up assessments were completed by 66, 53, and 41 patients at 3, 6, and 9 months, respectively. Reasons for non-completion were death ($n = 24$), assessment too burdensome ($n = 13$), no clinical follow-up due to poor neurological or physical condition ($n = 12$), and clinical follow-up in a different hospital ($n = 2$). Of the 66 patients with at least one follow-up, 35 patients (53.0%) had intracranial progression (in 18 patients (51.4%) due to new lesions only), 15 patients (22.7%) had a partial or complete response, and 16 patients (24.2%) had stable disease between time of treatment and last follow-up. There were no statistically significant differences in baseline characteristics between patients with and those without at least one follow-up HRQoL assessment, except for shorter median overall survival (17.1 months, 25 patients (37.9%) were censored, versus 2.7 months, 2 patients (7.7%) were censored, $p < 0.001$). HRQoL scores at baseline were comparable between patients with and those without at least one follow-up HRQoL assessment (Table 1).

### Table 3 Course and predictors of the HRQoL of patients with BM over time

| Time slope | Physical well-being | Social well-being | Emotional well-being | Functional well-being | FACT-General | Additional concerns | FACT Brain | Trial outcome index |
|------------|---------------------|-------------------|----------------------|-----------------------|--------------|---------------------|------------|----------------------|
| Time slope T0–T9 | $b$ (SE) | $-0.68$ (0.3) | $0.02$ (0.2) | $0.74$ (0.2) | $-0.05$ (0.3) | $0.03$ (0.6) | $0.75$ (0.4) | $0.71$ (0.9) | $-0.07$ (0.7) |
| $F$ value | 6.394 | 0.006 | 17.138 | 0.044 | 0.002 | 3.482 | 0.691 | 0.010 |
| $p$ value* | .012 | .939 | <.001 | .834 | .966 | .064 | .407 | .921 |
| Interval T0–T3 | $b$ (SE) | $-2.12$ (0.6) | $0.10$ (0.6) | $1.46$ (0.5) | $-1.01$ (0.6) | $-1.63$ (1.5) | $1.23$ (0.9) | $-0.46$ (2.0) | $-2.01$ (1.7) |
| Interval T3–T6 | $b$ (SE) | $0.46$ (0.7) | $-0.27$ (0.6) | $0.90$ (0.5) | $0.60$ (0.7) | $1.89$ (1.6) | $1.12$ (1.0) | $3.04$ (2.2) | $2.26$ (1.8) |
| Interval T6–T9 | $b$ (SE) | $-0.28$ (0.8) | $0.34$ (0.7) | $-0.49$ (0.6) | $0.27$ (0.8) | $-0.48$ (1.9) | $-0.45$ (1.2) | $-1.05$ (2.5) | $-0.73$ (2.1) |

**Interaction effect with time**

- **KPS**
  - $70–80$ vs. $90–100$ (ref)
    - $b$ | $0.304$ | $-0.410$ | $1.166$ | $0.439$ | $-1.193$ | $1.399$ | $2.430$ | $1.979$ |
    - $F$ value | 0.232 | 0.600 | 7.639 | 0.490 | 0.660 | 2.198 | 1.343 | 1.349 |
    - $p$ value* | .631 | .440 | .006 | .485 | .418 | .140 | .248 | .247 |
- **Systemic treatment**
  - Yes vs. no (ref)
    - $b$ | $0.759$ | $0.963$ | $-0.575$ | $0.165$ | $1.464$ | $0.406$ | $1.955$ | $1.377$ |
    - $F$ value | 1.664 | 3.868 | 2.189 | 0.081 | 1.160 | 0.216 | 1.011 | 0.759 |
    - $p$ value* | .199 | .051 | .141 | .783 | .283 | .643 | .316 | .385 |
- **Large intracranial tumor volume**
  - Large vs. medium (ref)
    - $b$ | $-1.622$ | $0.142$ | $0.232$ | $-0.489$ | $-1.815$ | $-2.684$ | $-4.581$ | $-4.962$ |
    - $F$ value | 4.984 | 0.055 | 0.234 | 0.466 | 1.174 | 6.223 | 3.665 | 6.509 |
    - $p$ value* | .027 | .815 | .629 | .496 | .280 | .014 | .057 | .012 |
- **Small intracranial tumor volume**
  - Small vs medium (ref)
    - $b$ | $-0.648$ | $0.496$ | $0.134$ | $-0.151$ | $-0.124$ | $-2.508$ | $-2.633$ | $-3.273$ |
    - $F$ value | 0.933 | 0.797 | 0.094 | 0.053 | 0.007 | 6.483 | 1.442 | 3.371 |
    - $p$ value* | .336 | .373 | .759 | .819 | .936 | .012 | .232 | .068 |
- **Number of BM**
  - 1–3 (ref) versus 4–10
    - $b$ | $-0.349$ | $0.284$ | $0.659$ | $-0.543$ | $0.206$ | $-1.580$ | $-1.262$ | $-2.243$ |
    - $F$ value | 0.56 | 0.47 | 0.37 | 0.55 | 1.29 | 0.83 | 1.84 | 1.50 |
    - $p$ value* | .536 | .544 | .075 | .326 | .874 | .058 | .495 | .136 |

BM brain metastases, CI confidence interval, HRQoL health-related quality of life, KPS Karnofsky Performance Status, ref reference category, SE standard error, T0 baseline, T3 3 months, T6 6 months, T9 9 months, vs versus

*Corrected alphas, using the Benjamini–Hochberg procedure (Benjamini and Hochberg 1995), were 0.013 for the overall models (time slope T0–T9), 0.017 for the time intervals of each HRQoL subscale, and 0.020 for the predictors of additional concerns and 0.010 for the predictors of the other HRQoL scales. Bold text indicates statistical significance

Both at baseline and at 9 months after GKRS, patients with BM had on average better social well-being and worse emotional well-being compared to the general American population (Brucker et al. 2005). There were no significant differences for physical well-being, functional well-being, and FACT-General (Table 2).
Health-related quality of life over time—group level

Over the course of 9 months, patients’ physical well-being worsened significantly whereas patients’ emotional well-being improved significantly. More specifically, between baseline and 3 months, there was a significant decrease in physical well-being and an increase in emotional well-being, after which scores did not change significantly between 3 and 6 months, nor between 6 and 9 months (Table 3). No significant change between baseline and the 9-month assessment was found for all other scales of the FACT-Br (Table 3). Analyses of interactions of time with baseline predictors demonstrated that patients with low (versus high) KPS had a significantly larger improvement in emotional well-being over time. Patients with medium intracranial tumor volumes at baseline had significantly less additional concerns over time compared to patients with small or large intracranial tumor volumes (Table 3).

Health-related quality of life over time—individual level

At the subscale level, for most patients (58.5–85.3%), scores remained stable or improved over 9 months after GKRS, except for physical well-being: scores on this subscale declined in 51.2% of patients. Decline in physical well-being was most pronounced between baseline and 3 months (45.5%) and between 6 and 9 months (41.5%) (Table 4). Between 6 and 9 months, a comparable number of patients showed an improvement (36.6%) in physical well-being. Regarding emotional well-being, scores improved in 46.3% of the patients and remained stable in 39.0% of the patients (Fig. 1). Improvement occurred especially during the first two intervals (T0–T3: 50.0% and T3–T6: 43.4%) (Table 4). Still, substantial groups of patients showed declines in social (36.6%) and functional (41.5%) well-being, and overall HRQoL (36.6%). Proportions of patients with declined, improved, and stable scores were comparable for these scales (Fig. 1).

At the patient level, over 9 months as well as between the intermediate assessments, most patients (41.5–47.2%) had both declines and improvements in different aspects of HRQoL. Smaller proportions of patients had only one or more declines in HRQoL aspects (15.1–29.3%), or only one or more improvements (24.4–34.0%). Almost none of the patients (1.5–3.8% between all intermediate measurements) showed no clinically meaningful changes at all on any of the HRQoL aspects (Fig. 2).
Discussion

The aim of this study was to evaluate the different aspects of HRQoL up to 9 months after GKRS in patients with 1–10 BM, both at group and individual level. Before, and at nine months after GKRS, compared to general population norms, patients’ emotional well-being was significantly lower whereas their social well-being was significantly higher. Worse emotional well-being before SRS (compared to the general population) has also been reported in a previous study in a group of patients with 1–4 BM (Habets et al. 2016). Emotional distress could be caused by the recent diagnosis of a serious life-threatening disease and the upcoming treatment (Verhaak et al. 2019a). On the other hand, patients may have experienced better social well-being due to strong social support from family, friends, and other groups, just before the upcoming treatment (Verhaak et al. 2019a) and at follow-up (Applebaum et al. 2014).

At group level, patients’ HRQoL remained stable over nine months, except for a significant decline in physical well-being and a significant improvement in emotional well-being, which both occurred during the first 3 months after GKRS. Previous studies also found stable HRQoL over time (Bragstad et al. 2017; Habets et al. 2016; Kirkpatrick et al. 2015; Skeie et al. 2017). In three of these studies, however, no decline in physical well-being was found (Bragstad et al. 2017; Kirkpatrick et al. 2015; Skeie et al. 2017), except for a trend towards a decline in physical well-being in one study (n = 24) (Kirkpatrick et al. 2015). Differences between studies may be explained by the inclusion of patients with a different initial performance status [KPS ≥ 70 (Kirkpatrick et al. 2015) versus KPS ≥ 60 (Bragstad et al. 2017; Skeie et al. 2017)]. Studies including patients with a lower initial KPS [KPS ≥ 60 (Bragstad et al. 2017; Skeie et al. 2017)] reported lower mean baseline physical well-being compared to studies including patients with a higher initial KPS [KPS ≥ 70 (Kirkpatrick et al. 2015)], as in our study. Mean physical well-being at 3, 6, and 9 months appeared to be comparable between studies.

In line with our group-level results, and the individual results in the study of van der Meer et al. (2018), for most individual patients HRQoL aspects remained stable or improved over 9 months after GKRS, except for a decline in physical well-being. This decline was most prominent during the first 3 months, and from 6 to 9 months after GKRS. Additionally, in line with our group results, improvement in emotional well-being was most pronounced in the early phase after GKRS.
There was, however, a degree of individual variation in HRQoL, both at subscale and patient level, that was not reflected in the group-level results. This was most clearly visible at patient level: most patients had both declines as well as improvements in the different aspects of HRQoL. These individual HRQoL changes within patients were masked at group level, which underlines the relevance of analyzing data both at group and at the individual patient level. Furthermore, our results showed that although patients’ general HRQoL (i.e., the FACT-G that is comprised of the four main HRQoL subscales) remained stable at group level over 9 months, scores on physical and emotional well-being changed considerably during this period (at group and individual subscale level). This supports the notion that HRQoL is a complex construct, and to apprehend the multifaceted nature of it, the different aspects of HRQoL should be measured and analyzed separately. Combining (subscale) scores into a total score (e.g., the FACT-G) may potentially mask particular issues concerning the different aspects of HRQoL (Verhaak et al. 2020).

The selected pre-GKRS predictors influenced scores on two out of eight aspects of HRQoL; lower baseline KPS was associated with significantly more improvement in emotional well-being over time, and medium baseline intracranial tumor volume was associated with less additional concerns over time. In line with previous studies, baseline number of BM did not influence HRQoL (Bragstad et al. 2017; Habets et al. 2016; Skeie et al. 2017) over time.

As mentioned before, maintaining HRQoL after treatment is a very important treatment goal. Our results indicate that HRQoL levels after GKRS are largely maintained except for a decline in physical well-being. This aspect includes questions regarding a lack of energy, pain, being bothered by side effects, feeling ill, and trouble meeting the needs of their family due to the physical condition. Especially in the first phase after treatment, patients reported a decline in physical well-being. In this early phase, these patients also experienced more physical fatigue as was reported in our previous publication (Verhaak et al. 2019b). This decline in physical well-being can have a large negative impact on a patient’s daily life; fatigue, pain and being bothered by side effects can cause patients to withdraw themselves from social activities, and not being able to physically provide for the needs of family and friends can have a negative effect on self-esteem. For patients experiencing problems with (declined) physical well-being, interventions such as psychoeducation, energy conservation, and coping strategies (Ahlberg et al. 2003; Day et al. 2016) might be helpful.

This study has several limitations. A heterogeneous study sample of patients with BM originating from several types of primary cancers was included. Specific systemic treatments, symptoms, and side effects related to the different primary cancers might have influenced HRQoL differently. Additionally, self-reported HRQoL may be positively or negatively biased by how a patient is feeling at the time of questionnaire administration (Demetriou et al. 2015). These feelings might not only be related to treatment factors but also to personal factors. Lastly, although a standard deviation of 0.5 is commonly used as cutoff for a minimally important difference, it is also considered a conservative estimate of a minimally important difference (Brucker et al. 2005; Ferrer and Pardo 2014; Norman et al. 2003). We used cut-offs provided by Brucker et al. (2005), based on clinical and subjective indicators, to determine individual meaningful differences specifically for the FACT-G. Using these cut-offs, which are close to 0.3 standard deviation, we may, however, have overestimated individual meaningful change in our sample. Additionally, there were no normative values available for the subscale additional concerns (and consequently for the FACT-Br total score and trial outcome index) based on the general population (Brucker et al. 2005), as this scale includes questions that are relevant for patients with brain tumors only.

Future studies are needed to evaluate the effect of psychological factors such as fatigue, mood, coping style, and personality, on HRQoL over time, as treatment and disease-related factors did not have substantial predictive value in this study. To better understand the influence of the different primary cancers on HRQoL, patients with BM should be analyzed separately based on their primary tumors.

Conclusion
Our results show that, even in patients with up to 10 BM, the number of BM did not influence change in HRQoL after GKRS, which is in line with previous studies in patients with mostly up to 4 BM. Both at group and at the individual subscale level, aspects of HRQoL remained stable or improved over 9 months after GKRS, except for a decline in physical well-being. There was, however, a degree of individual variation in HRQoL at patient level that was masked at group level. In terms of HRQoL, GKRS should be considered a treatment option for patients with up to 10 BM.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by EV and WS. The first draft of the manuscript was written by EV and WS and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This study was funded by ZonMw, the Netherlands organization for health research and development (Project Number 842003008).
Data availability  The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability  Not applicable.

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflict of interest.

Ethics approval  This study was approved by the Medical Ethics Committee Brabant (file NL53472.028.15).

Consent to participate  All patients gave written informed consent.

Consent for publication  Not applicable.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Achrol AS et al (2019) Brain metastases. Nat Rev Dis Primers 5:5
Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. The Lancet 362:640–650
Ahlulwalia MS, Vogelbaum MV, Chao ST, Mehta MM (2014) Brain metastasis and treatment. F1000Prime Reports 6
Applebaum AJ, Stein EM, Lord-Bessen J, Pessin H, Rosenfeld B, Breitbart W (2014) Optimism, social support, and mental health outcomes in patients with advanced cancer. Psycho-Oncol 23:299–306
Arvold ND et al (2016) Updates in the management of brain metastases. Neuro-Oncol 18:1043–1065
Benjamin Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289–300
Bragstad S et al (2017) Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study. J Neurosurg 129:71–83
Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28:192–211
Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579
Chen E et al (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20 and QLQ-C30. J Radiat Oncol 1:179–186
Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd edn. Lawrence Erlbaum Associates, Hillsdale
Day J et al (2016) Interventions for the management of fatigue in adults with a primary brain tumour. The Cochrane Library, London
Demetriou C, Ozer BU, Essau CA (2015) Self-report questionnaires. In: Cautin RL, Lilienfeld SO (eds) The encyclopedia of clinical psychology, Wiley, Malden, pp 1–6. https://doi.org/10.1002/9781118625392.wbecp507
FACTIT.org (2017) FACTIT: providing a voice for patients worldwide. FACTIT. https://www.facit.org.
Ferrer R, Pardo A (2014) Clinically meaningful change: false positives in the estimation of individual change. Psychol Assess 26:370
Habets EJ et al (2016) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-Oncol 18:435–444
Hunter GK et al (2012) Treatment of five or more brain metastases with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83:1394–1398
Kirkpatrick JP et al (2015) Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. Int J Radiat Oncol Biol Phys 91:100–108
Kotecha R et al (2017) Three or more courses of stereotactic radiosurgery for patients with multiply recurrent brain metastases. Neurosurgery 80:871–879
Lin NU et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16:e270–e278
Miller IA et al (2017) Quality of life following stereotactic radiosurgery for single and multiple brain metastases. Neurosurgery 81:147–155. https://doi.org/10.1093/neuros/nyw166
Nabors LB et al (2014) Central nervous system cancers, version 2.2014. J Natl Compr Canc Netw 12:1517–1523
Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54
Norman GR, Sloan JA, Wyrich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41:582–592
Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team (2018) nlme: Linear and nonlinear mixed effects models. R package version 3.1–137
R Core Team (2017) A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. URL https://www.R-project.org
Schimmel WC, Gehring K, Hanssens PE, Sitskoorn MM (2019) Cognitive functioning and predictors thereof in patients with 1–10 brain metastases selected for stereotactic radiosurgery. J Neurol 265:265–276
Skeie BS et al (2017) Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort. J Neurosurg 126:708–725
Smets E, Garssen B, Bonke B, De Haes J (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325
Soliman H, Das S, Larson DA, Sahgal A (2016) Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 7:12318
Tabouret E, Chinot O, Metelius P, Tallet A, Viens P, Goncalves A (2012) Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 32:4655–4662
Thavarajah N et al (2014) Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases. Support Care Cancer 22:1017–1028
Tsao MN (2015) Brain metastases: advances over the decades. Ann Palliat Med 4:225–232

Springer
van der Meer PB et al (2018) Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy. J Neurooncol 139:359–368

Verhaak E, Gehring K, Hanssens PEJ, Sitskoorn MM (2019a) Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. J Neurooncol 143:537–546. https://doi.org/10.1007/s11060-019-03186-z

Verhaak E, Schimmel WC, Sitskoorn MM, Bakker M, Hanssens PE, Gehring K (2019b) Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery. J Neurooncol 144:377–384

Verhaak E, Gehring K, Hanssens PEJ, Aaronson NK, Sitskoorn MM (2020) Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review. Support Care Cancer 28:473–484. https://doi.org/10.1007/s00520-019-05136-x

Verhage F (1964) Intelligentie en leeftijd: onderzoek bij Nederlands van twaalf tot zevenenzeventig jaar. Van Gorcum, Assen

Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708

Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Levin VA, Cella DF (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161

Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15:25

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.